Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review

BJU Int. 2008 Aug;102(4):426-31. doi: 10.1111/j.1464-410X.2008.07668.x. Epub 2008 Apr 11.

Authors

Bridget Candy¹, Louise Jones, Rachael Williams, Adrian Tookman, Michael King

Affiliation

¹ Marie Curie Palliative Care Research Unit, Department of Mental Health Sciences, Royal Free and University College Medical School, London, UK. b.candy@medsch.ucl.ac.uk

PMID: 18410431
DOI: 10.1111/j.1464-410X.2008.07668.x

No abstract available

Publication types

Meta-Analysis
Research Support, Non-U.S. Gov't
Review
Systematic Review

MeSH terms

Adolescent
Adult
Aged
Humans
Impotence, Vasculogenic / drug therapy*
Impotence, Vasculogenic / etiology
Male
Middle Aged
Phosphodiesterase Inhibitors / adverse effects
Phosphodiesterase Inhibitors / therapeutic use*
Prostatectomy / adverse effects
Prostatic Neoplasms / therapy*
Radiotherapy / adverse effects
Randomized Controlled Trials as Topic
Treatment Outcome

Substances

Phosphodiesterase Inhibitors